Lupin has followed through with its launch of the first generic version of Boehringer Ingelheim’s Spiriva HandiHaler (tiotropium bromide inhalation powder) 18 mcg/capsule in the US, positioning itself to capture share from a market worth north of $1.2bn.
Approved in June as the first dry powder inhaler approval from India for the US market, Lupin’s generic is indicated for the treatment of chronic obstructive pulmonary